| Abstrakt: |
In the quantitative step, after comparing the prices of 23 domestic biosimilars with the prices of the equivalent medicines in reference countries, the prices of 21 medicines were lower than the average prices of equivalent biosimilars and the prices of 18 medicines were even lower than the minimum price of the equivalent biosimilars in the reference countries. In addition, the production of these drugs in the country is indirectly effective in reducing the price of the main branded drugs in the country, so that in the case of imported branded biologic medicines, out of 28 medicines, the prices of 26 medicines were lower than the average prices in the reference countries and the prices of 23 medicines were even lower than the minimum of prices in the reference countries." Keywords: Biosimilars; Drugs and Therapies; Health and Medicine EN Biosimilars Drugs and Therapies Health and Medicine 2431 2431 1 10/16/23 20231020 NES 231020 2023 OCT 20 (NewsRx) -- By a News Reporter-Staff News Editor at Drug Week -- New study results on biosimilars have been published. [Extracted from the article] |
